Company Profile

Targeting Systems Inc
Profile last edited on: 7/22/08      CAGE:       UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
1996
First Award
1996
Latest Award
1996
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1453 North Cuyamaca Street
El Cajon, CA 92020
   (619) 562-1518
   targsys@aol.com
   www.targetingsystems.com
Location: Single
Congr. District: 53
County: San Diego

Public Profile

Targeting Systems was started in May 1996 entirely with the help of an SBIR phase I grant from the NIH. The company launched its first product line, Targefect within its first year of inception. There are now almost a 100 citations listing the use of these reagents for gene delivery. Although the company began as a one person operation, it now has about 50 products which are sold in over 15 countries worldwide. Our main focus has always been active research towards the development of novel technologies for applications in functional genomics. Our main areas of research include regulation of gene expression, alteration of cell function through intracellular delivery of functionally active proteins, and the development of ultra sensitive reporter gene assays based on unique luciferases. Targeting Systems was the first to develop a triple luciferase reporter gene assay based on a red and green emitting firefly luciferase in combination with a novel secreted luciferase (gaussia luciferase) and the first to develop and commercialize Gaussia luciferase as a reporter gene for mammalian cells. The novel luciferase technology developed here offers sensitivity over a 1000 times higher than the current technology based on firefly/renilla luciferases and has proved very useful for drug discovery applications involving high throughput screening. Our goal is to deliver innovative technology. The gaussia luciferase technology is very useful for tracking human stem cells and monitoring stem cell survival after implantation into animals, a step that is critical for assessing success of stem cell-based therapeutics in preclinical trials. The protein delivery technology developed at Targeting Systems is applicable for the expansion of stem cells by delivering functionally active proteins. These developments lead to the spinoff of a new company Pluristem Innovations in February 2007. Targeting Systems currently holds several issued and pending patents and is now planning to conduct research in the therapeutic potential of its products

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
10-14

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1996 1 NIH $97,505
Project Title: Novel Approach For Targeted Gene Delivery To The Liver

Key People / Management

  Rampyari R Walia -- President

Company News

There are no news available.